Educational Objectives Metastatic Breast Cancer: Scope of the Problem.

Slides:

Advertisements

Similar presentations

Miles D et al. Proc SABCS 2012;Abstract P

Advertisements

Integration of Taxanes in the Management of Breast Cancer

516 (32723) Phase III trial comparing AC (x4)taxane (x4) with taxane (x8) as adjuvant therapy for node-positive breast cancer: Results of N-SAS-BC02.

‍‍‍‍Chemotherapy in epithelial ovarian cancer. Dr.Azarm.

Herceptin® (trastuzumab) in combination with chemotherapy: pivotal metastatic breast cancer survival data 1.

Fabio Puglisi Dipartimento di Oncologia Azienda Ospedaliero Universitaria di Udine Antiangiogenic Treatment Mediterranean School of Oncology.

Drug Treatment of Metastatic Breast Cancer

Xeloda and Xeloda-based combinations in the treatment of MBC Steffan Kahlert Insert affiliation.

Taxane-pretreated metastatic breast cancer (MBC): investigational agents TTP = median time to disease progression OS = median overall survival.

CD-1 Update on the Safety of Erythropoietin Products in Patients With Cancer Martine George, MD Vice President, Therapeutic Area Head Hematology and Oncology.

Thymidine phosphorylase (TP) upregulation Dose- and time-dependent upregulation of TP in human colon cancer xenografts PaclitaxelDocetaxel.

A Meta-Analysis of Overall Survival Data from Three Randomized Trials of Bevacizumab (BV) and First-Line Chemotherapy as Treatment for Patients with Metastatic.

Use of Chemotherapeutic and Biologic Agents in Metastatic Breast Cancer Breast Cancer Update Medical Oncology Educational Forum May 21, 2005 Kathy D Miller.

OLD AND NEW ANTHACYCLINES: A STILL VALID OPTION IN BREAST CANCER TREATMENT True: Clara Natoli.

Herceptin ® : leading the way in metastatic breast cancer care Steffen Kahlert.

ESMO 2011 Breast Cancer Trastuzumab in untreated MBC Authors: CARE Faculty (Drs. Anil Joy and Sunil Verma) Date posted: October.

Highlights in the Management of Breast Cancer Nanoparticles incapsulated drugs Alessandra Fabi Medical Oncology Rome, 10 May 2013 Mediterranean School.

Treatment Regimens of HER2+ Adjuvant Patients (Actuals) Source: Genentech ASCO 2005 (data release) Nov 2006 (Approval)

Randomized Phase III Trial Comparing FOLFIRINOX (F: 5FU/Leucovorin [LV], Irinotecan [I], and Oxaliplatin [O]) versus Gemcitabine (G) as First-Line Treatment.

Phase I/II Trial of Docetaxel plus Oxaliplatin and 5-Fluorouracil (D-FOX) in Patients with Untreated, Advanced Gastric or Gastroesophageal Cancer Jaffer.

A Phase III Study (EMBRACE) of Eribulin Mesylate versus Treatment of Physician's Choice in Patients with Locally Recurrent or Metastatic Breast Cancer.

E2100 A Randomized Phase III Trial of Paclitaxel versus Paclitaxel plus Bevacizumab as First- Line Therapy for Locally Recurrent or Metastatic Breast Cancer.

Pritchard KI et al. Proc SABCS 2010;Abstract P

AVADO TRIAL David Miles Mount Vernon Cancer Centre, Middlesex, United Kingdom A randomized, double-blind study of bevacizumab in combination with docetaxel.

Taxanes — Taxanes are among the most active agents for metastatic breast cancer – Docetaxel, Paclitaxel, NabPaclitaxel. Anthracyclines – Doxorubicin, Epirubicin,

TAXOL® (paclitaxel) for Adjuvant Treatment of Node Positive Breast Cancer Oncologic Drugs Advisory Committee TAXOL® (paclitaxel) for Adjuvant Treatment.

1 Albumin-Bound Paclitaxel for the Treatment of Non-small Cell Lung Cancer Monotherapy Studies.

Four vs 6 Cycles of Doxorubicin and Cyclophosphamide (AC) or Paclitaxel (T) as Adjuvant Therapy for Breast Cancer in Women with 0-3 Positive Axillary Nodes:

CALYPSO Trial: Carboplatin & Pegylated Liposomal Doxorubicin (PLD) versus Carboplatin & Paclitaxel in Relapsed, Platinum- Sensitive Ovarian Cancer Pujade-Lauraine.

Impact of Bevacizumab (Bev) on Efficacy of Second-Line Chemotherapy (CT) for Triple- Negative Breast Cancer: Analysis of RIBBON-2 Brufsky A et al. Proc.

Agency Review of sNDA SE-006 DOXIL for Ovarian Cancer Division of Oncology Drug Products Office of Drug Evaluation 1 Center for Drug Evaluation.

A Phase III, Open-Label, Randomized, Multicenter Study of Eribulin Mesylate versus Capecitabine in Patients with Locally Advanced or Metastatic Breast.

Gemcitabine with Cisplatin or Paclitaxel in Metastatic Triple-negative Breast Cancer Xi-Chun Hu*, Binghe Xu, Li Cai, Zhong Hua Wang, Biyun Wang, Jian Zhang,

Results of a Phase 2, Multicenter, Single-Arm Study of Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic HER2-Negative Breast.

Neuropathy Is Not Associated With Clinical Outcomes in Patients Receiving Adjuvant Taxane-Containing Therapy for Operable Breast Cancer Bryan P. Schneider,

Single-agent nab-Paclitaxel Given Weekly (3/4) as First-line Therapy for Metastatic Breast Cancer (An International Oncology Network Study, #I )

Esophageal Cancer: A Critical Evaluation of Systemic Second-Line Therapy Christiane Maria Rosina Thallinger, Markus Raderer, and Michael Hejna J Clin Oncol.

Weekly Paclitaxel Combined with Monthly Carboplatin versus Single-Agent Therapy in Patients Age 70 to 89: IFCT-0501 Randomized Phase III Study in Advanced.

BACKGROUND & STUDY AIMS TARGETED CHEMOTHERAPY WITH ALBUMIN-BOUND PACLITAXEL (NAB-PACLITAXEL) FOR METASTATIC BREAST CANCER (MBC): WHICH BENEFIT FOR WHICH.

RANDOMIZED PHASE II STUDY OF NABPACLITAXEL, IN RECURRENT ADVANCED OR METASTATIC CERVICAL CANCER MITO CER-NAB Enrica Mazzoni, MD Medical Oncology & Breast.

Istituto Oncologico Veneto IRCCS

Belani CP et al. ASCO 2009; Abstract CRA8000. (Oral Presentation)

Alessandra Gennari, MD PhD

Management of metastatic and recurrent head and neck cancer

Vahdat L et al. Proc SABCS 2012;Abstract P

What do we do after FOLFIRINOX? Gemcitabine-Based Therapy is Standard

Swain SM et al. Proc SABCS 2012;Abstract P

Ruolo di carboplatino + nab-paclitaxel nel trattamento di I linea nel carcinoma polmonare non a piccole cellule P.Bidoli S.C. Oncologia Medica.

Abstract #LBA7511 Results of a Randomized, Phase III Trial of nab-Paclitaxel and Carboplatin Compared With Cremophor-based Paclitaxel and Carboplatin as.

Evolving Paradigms in Recurrent/Metastatic SCCHN

The Nurse View.

Metastatic HER2+ Breast Cancer: Resistance

Lo sviluppo clinico di nab-paclitaxel Discussant: Fabio Puglisi

Ospedale Misericordia, Grosseto

Her2-positive breast cancer: updating current best practice

The nab-Paclitaxel Difference

Learning Objectives. A Multidisciplinary Approach in Advanced NSCLC in the Era of Immuno-Oncology.

Optimizing the Treatment of Recurrent/Metastatic SCCHN

Program Goals. The Role of Chemotherapy in Improving Quality of Life in Advanced NSCLC.

Managing gBRCA-Positive Metastatic Breast Cancer

More Than Meets the Eye.

Reviewer: Dr. Sunil Verma Date posted: December 12th, 2011

Essential Concepts in the Use of Immunotherapies in Bladder Cancer

Baselga J et al. SABCS 2009;Abstract 45.

Advancing the Treatment of IBD With Biologics

Optimizing Targeted Therapy for HER2-Positive Advanced Breast Cancer: Considerations for Previously Treated Disease.

Selecting and Applying Chemotherapy

Optimizing Treatment in HR-Positive Breast Cancer: A Case-Based Discussion.

Efficacy of BSI-201, a PARP Inhibitor, in Combination with Gemcitabine/Carboplatin (GC) in Triple Negative Metastatic Breast Cancer (mTNBC): Results.

Response Rates and Adverse Event Rates in Phase II Trial

Presentation transcript:

Educational Objectives

Metastatic Breast Cancer: Scope of the Problem

Metastatic Breast Cancer: General Treatment Considerations

Therapeutic Goals/Endpoints in MBC

MBC: Impact of Chemotherapy

Treatment Options for Advanced Breast Cancer

First-Line Chemotherapy Options

Response Rates with Single-Agent Chemotherapeutic Agents in MBC

Highlights of the Evolution of Taxanes in Oncology

Taxanes in the Treatment of MBC

Conventional Taxanes: Pharmacologic and Pharmacodynamic Differences

Conventional Taxanes: Impact of Solvents

Albumin Role: Natural Carrier of Hydrophobic Molecules in Humans

Increased Intratumoral Concentration With nab-Paclitaxel

Differentiating the Taxanes: Toxicity

Making Taxanes Less “Tax-ing”

Taxane Toxicities

Randomized Comparison Between Taxanes

Taxanes: Premedication Guidelines

Taxane Hypersensitivity Reactions

Anemia

Differentiating the Taxanes: Efficacy

Pivotal Phase III Trials of Paclitaxel Single Agent and Combinations

Pivotal Phase III Trials of Docetaxel Single Agent and Combinations

TAX 311: Paclitaxel versus Docetaxel in Metastatic Breast Cancer

TAX 311: Paclitaxel Versus Docetaxel in Metastatic Breast Cancer – OS

TAX 311: Hematologic Toxicity

TAX 311: Non-Hematologic Toxicity

TAX 311: Quality of Life Analysis

Phase III Trial of nab-Paclitaxel vs Paclitaxel in MBC: Design

Phase III Trial of nab-Paclitaxel vs Paclitaxel in MBC: Results

Phase III Trial of nab-Paclitaxel vs Paclitaxel in MBC: TTP

Phase III Trial of nab-Paclitaxel vs Paclitaxel in MBC: OS

Phase III Trial of nab-Paclitaxel vs Paclitaxel in MBC: OS ( ≥ 2nd-line Patients)

nab-Paclitaxel vs Paclitaxel in MBC: Hematologic Toxicities

nab-Paclitaxel vs Paclitaxel in MBC: Non-Hematologic Toxicities

nab-Paclitaxel vs Paclitaxel in MBC: Neuropathy Resolution

Phase II Study of Weekly nab- Paclitaxel in Taxane-Refractory MBC

Taxanes: Cost-effectiveness Model

Cost-effectiveness Model: Methodology (cont.)

Costs per Cycle

Frequency of Grade 3/4 Toxicities (O’Shaughnessy 2003)

Treatment Costs per Toxicity for Taxane Therapy

Cost-effectiveness Ratios

Model Analysis of Total Costs

Conclusions